1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Amgen Testing Whether Different Is Better In Obesity, With Data Due This Year

GIP Receptor Antagonism Versus Agonism On Trial

 
• By Mandy Jackson

Amgen’s obesity drug MariTide will not have Phase II results until late 2024, but the company’s Q4 earnings call was dominated by questions seeking insight about the drug’s potential.

Weight scale instrument for measurement balance of people body concept
Amgen's Phase II MariTide data are expected in late 2024 • Source: Shutterstock

Amgen, Inc. has taken a divergent path with its obesity drug candidate maridebart cafraglutide (MariTide, AMG 133), a GLP-1 agonist and GIP receptor (GIPR) antagonist, which has delivered intriguing weight loss in a Phase I clinical trial despite differing from Eli Lilly and Company’s Zepbound (tirzepatide), which agonizes both GLP-1 and GIP. Phase II data for MariTide are not expected until late 2024, leaving observers impatient for data clarifying Amgen’s approach.

Key Takeaways

  • Amgen’s Q4 earnings call was dominated by questions about the company’s maridebart cafraglutide (MariTide, AMG 133), a GLP-1 agonist and GIP receptor (GIPR) antagonist.

While Amgen announced a 20% increase in Q4 revenue to $8.2bn, thanks to the closing of its $27.8bn acquisition of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Pipeline Watch: Eight Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

The Rise of China Biopharma – Five Themes In 2025

 
• By Andrew McConaghie

The growth of China’s biopharma sector has been perhaps the most significant sector trend this year – Scrip outlines five themes that have emerged during 2025 and in discussions at the recent Jefferies conference in London.

Amycretin Heads For Phase III In Type 2 Diabetes

 
• By Joseph Haas

New Phase II data in type 2 diabetes for Novo Nordisk’s GLP-1/amylin agonist amycretin shows significant weight loss and HbA1c-lowering potential. A Phase III trial is planned.

Kelonia Draws Attention With In Vivo CAR-T Myeloma Data

 
• By Alaric DeArment

The biotech will present data at the upcoming ASH meeting on three patients who achieved PRs or VGPRs with minimal residual disease negativity and no cases of neurotoxicity.

More from R&D

Amycretin Heads For Phase III In Type 2 Diabetes

 
• By Joseph Haas

New Phase II data in type 2 diabetes for Novo Nordisk’s GLP-1/amylin agonist amycretin shows significant weight loss and HbA1c-lowering potential. A Phase III trial is planned.

Kelonia Draws Attention With In Vivo CAR-T Myeloma Data

 
• By Alaric DeArment

The biotech will present data at the upcoming ASH meeting on three patients who achieved PRs or VGPRs with minimal residual disease negativity and no cases of neurotoxicity.

Zai Lab Takes Lead In DLL3 Lung Cancer ADC Race

 
• By Andrew McConaghie

Having built its reputation as the ‘Gateway to China’ for global firms, Zai is going global itself, moving its potential first-in-class ADC into Phase III development.